Accreditation Statistics

As of May 2, 2024

Cellular Therapy Entities

  • Accredited: 262
  • Applicants: 30

Cord Blood Banks

  • Accredited: 48
  • Applicants: 10

 

Initial Accreditations

  • Abu Dhabi Stem Cell Center, Abu Dhabi, United Arab Emirates | Cellular Therapy Product Processing with Minimal Manipulation
  • CHN - Complexo Hospitalar de Niterói, Rio de Janeiro, Brazil | Adult and Pediatric Allogeneic and Autologous Hematopoietic Progenitor Cell Transplantation, Marrow and  Peripheral Blood Cellular Therapy Product Collection, and Cellular Therapy Product Processing with Minimal Manipulation

     

A complete list of accredited organizations can be found at https://accredited.factglobal.org/.

Congratulations to Helen Heslop – Recipient of the 2023 ASH Mentor Award

Posted in :: 2023 Volume 7 :: Monday, December 11th, 2023

Congratulations to Dr. Helen Heslop, FACT Past President, for receiving the 2023 ASH Mentor Award. The American Society for Hematology (ASH) rewards outstanding mentors in the hematology community to recognize the value it places on mentorship. It defines mentoring as the process of guiding, supporting, and promoting the training and career development of others. The key roles of a mentor include, but are not limited to, providing: 

  • Intellectual growth and development 
  • Career development 
  • Professional guidance 
  • Advocacy 
  • Positive role modeling 

Per the ASH press release, “Dr. Heslop is a highly respected mentor who is known for her inclusivity and commitment to helping her mentees advance in their careers. She is an exceptional physician-scientist who has made significant and lasting contributions to the field of hematology. One of her remarkable achievements is her ability to nurture a diverse group of mentees, including female physician-scientists and individuals from backgrounds historically underrepresented in hematology. Many of her mentees have gone on to become successful independent investigators. Among those she mentors, Dr. Heslop is recognized as an ideal leader who is patient, kind, and one who consistently prioritizes the success of her trainees.

Dr. Heslop’s primary research focuses on the development of adoptive immunotherapies. By genetically modifying cells, she has worked to improve hematopoietic stem cell transplantation and cancer therapies. She strives to ensure that her findings are translated from the lab to clinical trials to improve the lives of individuals living with cancer and blood disorders.”